Acceptance of new tests that are alternatives to currently used toxicology tests is a topic of considerable importance in the field of toxicology. Carcinogenicity testing today normally includes 2-year studies in rats and mice of both sexes, following widely accepted procedures for husbandry; selection of dose levels; pathology and toxicity observations; and statistical interpretation of tumor data. These studies are usually preceded by tests for genetic toxicity and subchronic toxicity studies to select dose levels for the 2-year studies. Although these data are used for quantitative risk assessment, the mechanistic basis for effects is usually unknown. The series of studies is very expensive and requires 5 years or more to conduct. Alternative approaches are being developed that would provide more mechanistic information and hopefully would permit decisions to be made about carcinogenic potential without the need to conduct 2-year studies in rats and mice of both sexes. Decisions could be based on a profile of data rather than on the result of one test. Procedures for regulatory acceptance of new approaches for carcinogenicity testing are critical to future progress.
Introduction
Acceptance of alternative tests represents an opportunity to introduce new test methods into the toxicologist's armamentarium that will eventually reduce our dependence on resource-intensive whole animal tests. New test designs must be sensitive to the desire for mechanistically based data and the "three Rs"-reduction of the number of animals, refinements to enhance the well-being of animals, and replacements that do not use whole animals or lower species. This paper presents a strategy for using alternative tests for carcinogenesis screening. The term carcinogen is used here in the broad sense as an agent capable of increasing the incidence of malignant neoplasia after exposure. The concepts underlying the strategy apply to It has been suggested for some time that the use of the 2-year rodent bioassay as a screen, not as a definitive study for carcinogenic potential, but only as a screen. The reason for this has been that the 2-year bioassay as currently conducted is approximately one million dollars per study (single sex-species combination) and frequently gives equivocal results. Consequently, this is an expensive and time-consuming screen that often does not give definitive answers. This recommendation to seek alternatives was based on the assumption that the 2-year bioassay would be replaced with better test systems that had the desirable characteristics of being cheaper and faster, using fewer animals, and providing the appropriate sensitivity and specificity desired of a screen for carcinogenic potential. For many years, the desire to replace the 2-year rodent bioassay with other tests was a matter of talk with very little action to accomplish that objective. During the past 5 years, however, there has been clear movement toward acceptance of some alternatives to the 2-year study. Presently, one of the problems is the segregation of toxicologists into three groups in response to a movement toward alternative test systems. First, are those who now recommend no change and a continuation of 2-year studies in two species of both sexes when there is a need for carcinogenicity data. A second group supports the proposal of the International Committee for Harmonization for drugs (1) ; that is, when carcinogenicity data are required, the studies would be conducted in one rodent species and be supplemented by other data. The default rodent species would be the rat. A third group recommends simply conducting carcinogenicity studies in one species of rodent, preferably the rat, with no requirement for other data.
None of these choices is clearly right or wrong. One of the problems with our approach over the last two decades is that we have accepted the standard 2-year bioassay, typified by the study design that has been used by the National Toxicology Program (NTP) in the past, as the standard study design for all chemicals, reflecting the philosophy that "one size fits all." As we learn more about the modes ofaction ofcarcinogens, it becomes clear that some other alternative must be considered and that the selection of studies must be tailored to the individual chemical. Change is required, however. There are a number of often-cited reasons for change that are obvious, such as the cost of 2-year studies, the use of large numbers of animals, the duration required to conduct the studies, and the uncertainty of the outcome in terms of equivocal answers or extrapolation of results to humans. For example, because of the high background incidence of liver tumors in male B6C3F1 mice, discussions continue on the relevance of this tumor for humans.
There are some less obvious reasons for change that must also be pointed out. Twoyear rodent studies are empirical in nature; the assumption is that the development of most tumors, even by unknown mechanisms, is predictive of some tumorigenic potential in humans. Some notable exceptions are kidney tumors formed in male rats due to an accumulation of the a2p-globulin protein and bladder tumors due to the formation of crystals in the urine.
The historical database we have relied on is not as useful as was assumed. For example, there has been genetic drift in many of the strains of animals believed to be genetically pure strains. The observation that the body weight of certain test animals has increased progressively during the past few years has complicated the use of control data (3) . Animals live a shorter time and the profile of tumors is different. Therefore, control data generated 15 years ago, when mean body weights were considerably less, cannot be the basis for comparisons to studies conducted today in heavier animals (4). Consequently, we have moved away from using historical databases to the use of contemporary databases, eliminating control data from earlier years. The primary emphasis is now given to concurrent control data, again recognizing the fact that control data from previous years are less valuable than concurrent control data.
We have been concerned about the predictivity of 2-year bioassays over the last decade as our experience and knowledge have expanded. This issue must be addressed as we consider the benefit of alternative test systems. New test systems reflect new scientific developments, that is, new models that are mechanistically based and reflect the increasing diversity of mechanisms that contribute to the development of the carcinogenic response. Such information is not obtained from 2-year rodent studies as they have been conducted in the past.
One of the evaluative measures of the 2-year study as a gold standard is the predictiveness observed between rats and mice. The species concordance has been evaluated and reviewed by many investigators, induding DiCarlo (5) (8) and Crouch (9) concluded that there was good species correlation for those chemicals that were carcinogenic in both rats and mice. The potencies of the two species were generally within a factor of 20 of each other. Note that this is true only for chemicals that were carcinogenic in both species.
Using the carcinogenic potency database compiled by Gold and co-workers (10) on 770 compounds, Gaylor and Chen (11) showed good agreement for carcinogenic potency, on the average, among rats, mice, and hamsters for various routes of exposure. However, variability was substantial, with differences generally within a factor of 100. For 69 NTP chemicals that produced tumors in the same sex and tissue site, Chen and Gaylor (12) showed that carcinogenic potencies for rats and mice were generally within a factor of40. Despite the variability, it has been argued that the correlation of potencies between rats and mice supports extrapolation to humans. However, the studies were only conducted on concordant chemicals, i.e., chemicals that produce tumors in both rats and mice.
Tennant et al. (13) Gaylor (19) , if 100 animals had been used per dose group rather than 50 animals, with the resulting increased power of detection and the same incidence rates, it appears that at least 70% of NTP chemicals would be considered animal carcinogens. These results suggest that the standard 2-year rodent bioassay employing high-dose levels may, in effect, be a long-term toxicity test in which cancer is often one of the biologic manifestations, limiting its usefulness as a good screen for carcinogenicity.
Our scientific knowledge about the mechanisms of carcinogenesis is far different today than it was in the 1970s when the 2-year bioassay was first adopted as a routine screen. In addition to information from genetic toxicity assays and structural alert information, it is apparent today that a broad range of toxicologic and genetic toxicity data would be helpful in supporting predictions about the probable carcinogenicity of a substance. Such information would indude cell proliferation data, information on apoptosis, peroxisome proliferation capabilities, impact on hormonal profile, production of cz2p-globulin, profile of metabolism, and other information.
In summary, with the 2-year bioassay, the rat-mouse prediction for carcinogenicity is about 75% accurate. The bioassay is poor at detecting the effect of weak carcinogensand is not useful for evaluation of the mechanisms of carcinogenicity, an array of information much more diverse than anticipated when the bioassay was first adopted over two decades ago. These limitations raise obvious questions about the usefulness of the bioassay as the gold standard from which to draw conclusions regarding alternatives to the 2-year bioassay, and must be considered as we move toward accepting alternatives to the standard rodent bioassay.
Alternative Strategies
Within the U.S. FDA, we have had considerable discussion over the past 3 years regarding the desire to develop a strategy for carcinogenicity testing that would permit regulatory decisions to be made on data sets that may not include the results of traditional 2-year studies in both sexes of two rodent species. Conclusions about carcinogenic potential should be based on a profile of toxicologic data, not just on a bioassay result. The weight of evidence is more important than an approach that depends on a decision tree. Conclusions should consider data that describe mechanisms of carcinogenesis. One such strategy might include use of data from new test systems such as the transgenic models TG:p53+/-, the p53 hemizygote, and the transgenic model TG:AC. The relevancy of the transgenic models to humans must be evaluated. Another test system currently being reevaluated is the newborn mouse assay.
A strategy that indudes the use of these test systems is diagrammed in Figure 1 . Assuming there is human exposure and therefore a desire to collect information about carcinogenic potential, one would base preliminary estimates on physical chemical properties of the substance, structural alert information, information from computer-based predictive systems, and the results of the genetic toxicity screen. On the basis of this information, one would conclude that a substance is either nongenotoxic or genotoxic. If the substance is strongly genotoxic, one could conclude that the chemical would be a carcinogen if tested in a 2-year study, or the alternate would be to proceed with the 2-year rodent study. However, because about one-third of mutagens are not carcinogenic in the standard bioassay and about one-third of carcinogens are not mutagenic in common tests, it probably would be prudent to 
